EURO SHOCK
  • Home
  • Researchers' area
    • About EUROSHOCK
    • Work Packages
    • Intranet
  • Patients' area
    • About EUROSHOCK
  • Recruiting Centres
  • Partners
  • News and Media
    • News
  • Home
  • Researchers' area
    • About EUROSHOCK
    • Work Packages
    • Intranet
  • Patients' area
    • About EUROSHOCK
  • Recruiting Centres
  • Partners
  • News and Media
    • News

New Horizon 2020 EURO SHOCK study sets out to improve the outcome for patients with cardiogenic shock

1/12/2017

0 Comments

 
The new EURO SHOCK study is to receive € 6.5 million from the EU, to assess a new procedure of treatment approach for patients suffering cardiogenic shock. The project unites the foremost physicians in cardio-vascular medicine from across Europe, and is determined to become a bench-mark study on one of the few last challenges in this field. The ambition for EURO SHOCK is nothing less than to reduce the mortality associated with cardiogenic shock – a life threatening condition following a severe coronary heart attack.

Cardio-vascular diseases are responsible for more than 4 million deaths across Europe every year. Overall this type of disease is estimated to cost the European economy € 210 billion a year. Acute myocardial infarction, also more commonly known as heart attacks, evolve in about 10% of all cases into cardiogenic shock (in Europe 60.000-70.000 cases per year) with a 50% mortality rate in the first 30 days. This number is even higher in women and elderly patient groups.

Read More
0 Comments

    Author

    Write something about yourself. No need to be fancy, just an overview.

    Archives

    February 2019
    December 2018
    November 2018
    September 2018
    December 2017

    Categories

    All

    RSS Feed

Picture
This project has receiver funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 754946.

© accelopment 2019.
ALL RIGHTS RESERVED

Disclaimer |  Intranet